Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Expected to Announce Quarterly Sales of $31.15 Million

Equities analysts expect Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) to post sales of $31.15 million for the current quarter, according to Zacks. Six analysts have issued estimates for Aerie Pharmaceuticals’ earnings. The lowest sales estimate is $30.05 million and the highest is $31.91 million. Aerie Pharmaceuticals posted sales of $24.68 million during the same quarter last year, which suggests a positive year-over-year growth rate of 26.2%. The business is expected to announce its next earnings results on Thursday, February 24th.

On average, analysts expect that Aerie Pharmaceuticals will report full-year sales of $110.59 million for the current fiscal year, with estimates ranging from $109.52 million to $111.38 million. For the next year, analysts forecast that the firm will report sales of $154.96 million, with estimates ranging from $138.02 million to $184.94 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that cover Aerie Pharmaceuticals.

Aerie Pharmaceuticals (NASDAQ:AERI) last released its quarterly earnings results on Thursday, November 4th. The company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.10). Aerie Pharmaceuticals had a negative net margin of 159.85% and a negative return on equity of 1,531.00%. The business had revenue of $29.31 million during the quarter, compared to analysts’ expectations of $29.13 million. During the same period in the previous year, the business earned ($0.65) EPS.

Several analysts have weighed in on the company. Needham & Company LLC lowered their price target on Aerie Pharmaceuticals from $24.00 to $22.00 and set a “buy” rating on the stock in a report on Friday, November 5th. HC Wainwright reissued a “buy” rating and set a $29.00 price objective on shares of Aerie Pharmaceuticals in a report on Thursday, September 16th. Finally, Zacks Investment Research cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating and set a $12.00 price objective on the stock. in a report on Monday, November 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $21.33.

NASDAQ:AERI opened at $9.89 on Thursday. The firm has a 50-day simple moving average of $11.83. Aerie Pharmaceuticals has a twelve month low of $9.15 and a twelve month high of $21.30. The stock has a market cap of $468.37 million, a PE ratio of -2.74 and a beta of 0.87.

A number of institutional investors have recently made changes to their positions in the business. Parametric Portfolio Associates LLC increased its stake in Aerie Pharmaceuticals by 0.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 112,664 shares of the company’s stock worth $1,804,000 after purchasing an additional 788 shares during the period. Eqis Capital Management Inc. increased its stake in Aerie Pharmaceuticals by 0.7% in the 2nd quarter. Eqis Capital Management Inc. now owns 119,228 shares of the company’s stock worth $1,909,000 after purchasing an additional 846 shares during the period. California State Teachers Retirement System increased its stake in Aerie Pharmaceuticals by 1.7% in the 3rd quarter. California State Teachers Retirement System now owns 59,405 shares of the company’s stock worth $677,000 after purchasing an additional 999 shares during the period. Royal Bank of Canada increased its stake in Aerie Pharmaceuticals by 45.2% in the 1st quarter. Royal Bank of Canada now owns 3,461 shares of the company’s stock worth $61,000 after purchasing an additional 1,077 shares during the period. Finally, LPL Financial LLC increased its stake in Aerie Pharmaceuticals by 4.6% in the 2nd quarter. LPL Financial LLC now owns 24,722 shares of the company’s stock worth $396,000 after purchasing an additional 1,084 shares during the period.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L.

See Also: Stock Market – What is a circuit breaker?

Get a free copy of the Zacks research report on Aerie Pharmaceuticals (AERI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Aerie Pharmaceuticals (NASDAQ:AERI)